CG Oncology, Inc. Common stock

CGONNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
53.72 USD
↘ 2.37 (4.23%)AT CLOSE (11:59 AM EDT)
53.70
↘ 0.02 (0.04%)
POST MARKET (AS OF 05:23 PM EDT)
Post Market
AS OF 05:23 PM EDT
53.70
↘ 0.02 (0.04%)
🔴Market: CLOSED
Open?$55.85
High?$56.78
Low?$53.52
Prev. Close?$56.09
Volume?967.3K
Avg. Volume?895.5K
VWAP?$55.01
Rel. Volume?1.08x
Bid / Ask
Bid?$21.59 × 200
Ask?$67.00 × 400
Spread?$45.41
Midpoint?$44.30
Valuation & Ratios
Market Cap?4.7B
Shares Out?88.2M
Float?55.6M
Float %?68.9%
P/E Ratio?N/A
P/B Ratio?4.34
EPS?-$2.12
Dividend?0.00%
Ex-Dividend?N/A

CGON is currently priced at $53.72. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, CGON trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
142
Market Cap
4.7B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.cgoncology.com
Listed
2024-01-25
Address
3000 PEGASUS PARK DRIVE
DALLAS, TX 75247
Phone: (949) 409-3700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
100
Momentum?
18
Short Sent.?
19
Piotroski F-Score?2/9Weak
Altman Z-Score?65.35Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?16.51%High
Short Interest?9.2M
Days to Cover?10.0
Free Float55.6M
Avg Daily Volume918.0K
Settlement Date2026-05-15
Financial Health
Current Ratio?31.30Strong
Quick Ratio?31.25Strong
Cash Ratio?0.96Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
41
4.34FAIR▾
P/S?
Peers
100
S&P
3
934.38HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-22.1CHEAP▾
EV/Sales?
Peers
100
S&P
3
928.33HIGH▾
Returns & Efficiency
ROE?
S&P
8
-17.1%WEAK▾
ROA?
S&P
3
-16.5%WEAK▾
Cash Flow & Enterprise
FCF?$-160434000
Enterprise Value?$4.7B
Fundamentals ratios updated end of day
MarketsMoversWatchlist